Targeted therapy for high-risk BRAF-mutated thyroid cancer
Treatments studied
Part of Cancer, Hormones & metabolism clinical trials.
This trial tests two targeted drugs, vemurafenib and cobimetinib, for people with high-risk thyroid cancer that has a specific BRAF V600E mutation. The goal is to see if this combination can help prevent the cancer from coming back after surgery or other initial treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a certain type of thyroid cancer that has a BRAF V600E gene mutation.
- Your cancer must be considered "high risk" for recurrence, meaning it has spread outside the thyroid, involves large lymph nodes, or has other concerning features.
- You cannot have had previous treatment with drugs that target BRAF or MEK (like vemurafenib or cobimetinib) or certain other targeted therapies.
- You must be at least 18 years old, have good organ function (kidneys, liver, blood counts), and controlled blood pressure.
- You must be willing to avoid pregnancy or father a child by using effective birth control during and for a year after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests dabrafenib plus trametinib in people whose solid tumors have a BRAF V600E mutation that cannot be fully removed by surgery or has spread. It looks at whether these targeted medicines can shrink tumors and control the disease.
This trial compares a targeted therapy pill combination (dabrafenib and trametinib) with cabozantinib or chemotherapy for people with a specific type of advanced thyroid cancer (differentiated thyroid cancer) that has a BRAF V600E mutation. It aims to find which treatment works better after previous treatments have stopped working.
This trial tests whether giving targeted drugs before surgery can help shrink advanced thyroid cancers, making them easier to remove. It uses your tumor's genetic profile to choose the best treatment for you.
This trial tests whether giving a targeted therapy pill (which attacks cancer cells with a BRAF mutation) before and after surgery can help treat anaplastic thyroid cancer that hasn't spread to other organs. It's for people whose cancer has a specific gene change (BRAF V600E or V600K) and who are healthy enough for surgery.
This trial tests whether combining two targeted cancer medicines—vemurafenib and cobimetinib—can treat adults whose tumors have a specific “BRAF V600” mutation. You may be screened with blood tests and a tissue biopsy before starting treatment.
This trial tests two oral medications, avutometinib and defactinib, for people with advanced thyroid cancer that has specific genetic changes. The goal is to see if these drugs can shrink tumors or slow their growth.
Hear when a new Thyroid Gland Follicular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.